KRM Ayurveda Q2 Results 2026: PAT ₹8 Cr +103%, Revenue ₹35 Cr +41%
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹35Cr
- +40.7% YoY
- +7.4% QoQ
- Net profit
- ₹8Cr
- +103.2% YoY
- −9.4% QoQ
- Margin
- 30.8%
- +5.6 pp YoY
- −6.4 pp QoQ
Guidance rank: #2 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
KRM Ayurveda Ltd Q2 FY27 key numbers
- Revenue
- Q2 FY27 EBITDA: ₹1,126.33 Lakhs, up 63.60% YoY.
As stated in KRM Ayurveda Ltd's Q2 FY27 investor presentation · published 14 Nov 2026. Reported figures, not investment advice.
Based on KRM Ayurveda Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Total Income: ₹3,529.95 Lakhs, a 48.08% year-on-year (YoY) increase from Q2 FY26 (₹2,383.80 Lakhs). Q2 FY27 Total Income: ₹3,529.95 Lakhs, up 48.08% YoY.
From KRM Ayurveda Ltd's Q2 FY27 earnings-call transcript · updated 14 Nov 2026.
How did KRM Ayurveda's revenue grow in the September 2026 quarter?
- Q2 FY27 Total Income: ₹3,529.95 Lakhs, a 48.08% year-on-year (YoY) increase from Q2 FY26 (₹2,383.80 Lakhs).
- Q2 FY27 EBITDA: ₹1,126.33 Lakhs, up 63.60% YoY.
- Q2 FY27 PAT: ₹814.64 Lakhs, up 95.37% YoY.
- H1 FY27 Total Income: ₹6,816.50 Lakhs, a 40.10% YoY increase from H1 FY26 (₹4,865.43 Lakhs).
- H1 FY27 EBITDA: ₹2,382.40 Lakhs, up 79.81% YoY.
2 more points from KRM Ayurveda Ltd's call on revenue
Create a free account to keep reading this call
What happened to KRM Ayurveda's margins in Q2 FY27?
Q2 FY27 Total Income: ₹3,529.95 Lakhs, up 48.08% YoY
Locked: what KRM Ayurveda Ltd said on margins
Also locked on this page: fundraising
Free account, 30 seconds. No card needed.
What capex is KRM Ayurveda planning?
- Two new hospitals added in FY26:
- MSS Hospital, Pitampura: 23 beds, 5,631 sq ft, established and disclosed June 16, 2026
- Sector-47, Gurugram: 80 beds, ~27,500 sq ft, board approved July 9, 2026; existing unit at ~90–100% capacity
- Funded entirely through the Company’s own funds
- Three new Day Care Centres commenced between April and September 2026:
- Janakpuri, New Delhi: 2,761 sq ft, 9-year lease, commenced April 10, 2026
- Navi Mumbai (Vashi, Sector-17): 2,100 sq ft, 5-year lease, commenced September 3, 2026
2 more points from KRM Ayurveda Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is KRM Ayurveda raising money or cutting debt?
The presentation mentions a "Rapid Expansion & IPO Filing" in 2025, indicating a plan to raise funds…
Locked: what KRM Ayurveda Ltd said on fundraising
Also locked on this page: margins
Free account, 30 seconds. No card needed.
How big is KRM Ayurveda's order book?
- Revenue, EBITDA, and profitability metrics are shared, but no reference to orders or pending sales.
- Emphasis is on integrated healthcare services, product manufacturing, digital health expansion, and market growth rather than order-specific data.
KRM Ayurveda Ltd — Quarterly revenue & net profit
KRM Ayurveda Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q1 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 35 | 25 | +40.7% | 32 | +7.4% |
| Operating profit (EBITDA) | 11 | 6 | +72.1% | 12 | -11.1% |
| Operating margin | 30.8% | 25.17% | +5.6 pp | 37.19% | -6.4 pp |
| Profit before tax | 11 | 5 | +100.6% | 12 | -11.2% |
| Net profit (PAT) | 8 | 4 | +103.2% | 9 | -9.4% |
| EPS (₹) | 3.87 | 2.70 | +43.3% | 4.27 | -9.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹35 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
What KRM Ayurveda's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Orchid Pharma (Q2 FY27)
4,280.8 lakhs (~14.3% increase). Key results statement takeaways from Orchid Pharma Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Gujarat Themis Biosyn (Q2 FY27)
Standalone: ₹4,745.52 Lakhs . Key results statement takeaways from Gujarat Themis Biosyn Ltd's Q2 FY27 results statement — and how it ranks against sector peers
- Nectar Lifescience (Q2 FY27)
Quarterly EBITDA**: ₹52.7 crore, down 88% YoY . Key results statement takeaways from Nectar Lifescience Ltd's Q2 FY27 results statement — and how it ranks again
- Gufic BioScience (Q2 FY27)
288.4 crore, up from Rs. Key investor presentation takeaways from Gufic BioSciences Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- 2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
KRM Ayurveda Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were KRM Ayurveda Ltd Q2 FY27 results?
Q2 FY27 Total Income: ₹3,529.95 Lakhs, a 48.08% year-on-year (YoY) increase from Q2 FY26 (₹2,383.80 Lakhs). Q2 FY27 Total Income: ₹3,529.95 Lakhs, up 48.08% YoY.
What is KRM Ayurveda Ltd share price analysis?
KRM Ayurveda Ltd currently shows a neutral. The stock trades at a P/E of 19.4 with a market cap of ₹489 Cr. Investors should review the full earnings analysis for detailed insights.
Is KRM Ayurveda Ltd planning capital expenditure?
Two new hospitals added in FY26:.
Keep KRM Ayurveda Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.